Trial Profile
A Randomised Controlled Trial of Early Intervention in Patients HospItalised With COVID-19: Favipiravir and StaNdard Care vErsEs Standard CaRe
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Azithromycin (Primary) ; Favipiravir (Primary) ; Favipiravir (Primary) ; Hydroxychloroquine (Primary) ; Hydroxychloroquine (Primary) ; Zinc sulfate (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms PIONEER
- 17 Nov 2021 Status changed from active, no longer recruiting to completed.
- 28 May 2021 Planned End Date changed from 31 Mar 2021 to 25 Jun 2021.
- 28 May 2021 Planned primary completion date changed from 31 Mar 2021 to 25 Jun 2021.